Compare · MRNA vs SLXN
MRNA vs SLXN
Side-by-side comparison of Moderna Inc. (MRNA) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 8943.0x SLXN ($2.7M).
- Over the past year, MRNA is up 99.5% and SLXN is down 97.9% - MRNA leads by 197.4 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 1 for SLXN).
- MRNA has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- Moderna Inc.
- Silexion Therapeutics Corp
- Price
- $61.80-2.14%
- $2.58+1.18%
- Market cap
- $24.53B
- $2.7M
- 1M return
- +11.57%
- -3.73%
- 1Y return
- +99.48%
- -97.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 10
- 1
- Recent ratings
- 25
- 0
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
Latest SLXN
- SEC Form DEFA14A filed by Silexion Therapeutics Corp
- Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- SEC Form EFFECT filed by Silexion Therapeutics Corp
- SEC Form 424B3 filed by Silexion Therapeutics Corp
- SEC Form DEF 14A filed by Silexion Therapeutics Corp
- Silexion Therapeutics to Attend BIO International Convention 2026
- SEC Form S-3 filed by Silexion Therapeutics Corp
- CSO and CDO Shirvan Mitchell was granted 6,000 units of Ordinary Shares, increasing direct ownership by 215% to 8,789 units (SEC Form 4)
- CFO and Secretary Horenshtein Hadar Mirit was granted 7,500 units of Ordinary Shares, increasing direct ownership by 150% to 12,515 units (SEC Form 4)